OABI
What one share of Omniab holds
Services – Commercial Physical and Biological Research
OmniAb, Inc. licenses cutting-edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts.
Omniab’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.31 |
|---|---|
| Profit | −$0.35 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.15 |
| Cash and investments | $0.17 |
| Book value | $1.79 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | $0.42 | −$0.33 | $0.05 | −$0.12 | — | — |
| 2022 | $0.69 | −$0.26 | $0.20 | −$0.24 | — | $2.96 |
| 2023 | $0.34 | −$0.51 | $0.02 | $0.01 | — | $2.69 |
| 2024 | $0.26 | −$0.61 | $0.02 | −$0.41 | — | $2.37 |
| 2025 | $0.16 | −$0.57 | $0.01 | −$0.33 | — | $1.85 |